55P Adjuvant gemcitabine-based chemotherapy for biliary tract cancer: Pooled analysis of the BCAT and PRODIGE-12 studies
Julien Edeline(Inserm), Tomoki Ebata(Nagoya University), J. Watelet(Centre Hospitalier Régional et Universitaire de Nancy), David Malka(Inserm), Katsuhiko Uesaka(Shizuoka Cancer Center), Yoshiyasu Ambo(Hokkaido University of Science), Masayuki Ohtsuka(Chiba University), Jean–Marc Phelip(Centre Hospitalier Universitaire de Saint-Étienne), Pascal Hammel(Hôpital Paul-Brousse), M. Benabdelghani(Levi Strauss (United States)), Masahiko Ando(Nagoya University Hospital), Masaru Konishi(Shizuoka Cancer Center), Aurélie Bertaut(Institut de Cancérologie de Bourgogne), C. Jouffroy(UniCancer Group), Satoshi Hirano(Hokkaido University of Science), Masato Nagino(Daido University), Yuji Kaneoka(Ogaki Municipal Hospital), Masakazu Yamamoto(Tokyo Women's Medical University), JP Joly(Centre Hospitalier Universitaire Amiens-Picardie), Christophe Louvet(Institute Mutualiste Montsouris)
Cited by 1
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k